Retrospective OCT Analysis of Sphingosine-1-Phosphate Modulator Fingolimod in Multiple Sclerosis
Purpose: Sphingosine-1-phosphate (S1P) plays a pivotal role in cells as a bioactive lipid mediator, with emerging evidence suggesting that it may play a role in retinal ganglion cell survival, axonal growth, retinal pigment epithelium (RPE) barrier function, and photoreceptor function. While previou...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-11-01
|
| Series: | Ophthalmology Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666914525001915 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849228334521647104 |
|---|---|
| author | Wilson X. Wang, MD, MPhil Helen Rossmiller, BS Henok Getahun, BS Aditya Santoki, BS Dana C. Perantie, MPH Robert T. Naismith, MD Rajendra S. Apte, MD, PhD |
| author_facet | Wilson X. Wang, MD, MPhil Helen Rossmiller, BS Henok Getahun, BS Aditya Santoki, BS Dana C. Perantie, MPH Robert T. Naismith, MD Rajendra S. Apte, MD, PhD |
| author_sort | Wilson X. Wang, MD, MPhil |
| collection | DOAJ |
| description | Purpose: Sphingosine-1-phosphate (S1P) plays a pivotal role in cells as a bioactive lipid mediator, with emerging evidence suggesting that it may play a role in retinal ganglion cell survival, axonal growth, retinal pigment epithelium (RPE) barrier function, and photoreceptor function. While previous studies have documented associated ophthalmic effects such as fingolimod-associated macular edema, the specific impact of S1P receptor modulators on inner and outer retinal layer thicknesses requires further elucidation. Design: Retrospective case series. Subjects: A total of 44 patients (86 eyes) with multiple sclerosis (MS) treated with fingolimod between 2011 and 2023 at the John L. Trotter Multiple Sclerosis Center at Washington University in St. Louis. Methods: Eligible participants were those with baseline and follow-up OCT images conducted at or prior to S1P initiation and at the most recent visit. The peripapillary retinal nerve fiber layer (pRNFL), ganglion cell layer (GCL), central subfield thickness (CST), macular volume (MV), RPE, and photoreceptor thickness were determined through OCT segmentation. Generalized estimating equations were constructed incorporating relevant covariates. Main Outcome Measures: Annualized rate of change of specified retinal layer thickness. Results: The mean age was 49.4 ± 10.8 years and time between baseline and follow-up OCTs ranged from 2 months to 6.4 years with a median of 1 year, interquartile range 0.42 to 2.33. The annualized rate of change of pRNFL and CST were 0.022 [–0.363, 0.406] μm/year, and −1.37 [−3.11, 0.38] μm/year, whereas GCL and MV showed significant thinning of −0.231 [−0.430, −0.032] μm/year and −0.024 [–0.047, −0.001] mm3/year, respectively. Retinal pigment epithelium and photoreceptor layer thickness remained largely stable over time at 0.070 [−0.140, 0.280] μm/year and 0.673 [−0.218, 1.561] μm/year, respectively. Conclusions: Patients with MS on S1P modulators exhibited significant GCL and MV thinning with outer retina layer thickness preservation, providing insight into the potential retinal effects of S1P modulation in the setting of MS-related neurodegeneration. Prospective studies with standardized imaging intervals and appropriate controls are needed to distinguish the specific retinal effect of S1P modulation from MS neurodegeneration and enable more precise OCT interpretation of the retina in monitoring MS disease progression. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. |
| format | Article |
| id | doaj-art-e769e75f737f49deacffee5c30bf1efa |
| institution | Kabale University |
| issn | 2666-9145 |
| language | English |
| publishDate | 2025-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Ophthalmology Science |
| spelling | doaj-art-e769e75f737f49deacffee5c30bf1efa2025-08-23T04:49:20ZengElsevierOphthalmology Science2666-91452025-11-015610089310.1016/j.xops.2025.100893Retrospective OCT Analysis of Sphingosine-1-Phosphate Modulator Fingolimod in Multiple SclerosisWilson X. Wang, MD, MPhil0Helen Rossmiller, BS1Henok Getahun, BS2Aditya Santoki, BS3Dana C. Perantie, MPH4Robert T. Naismith, MD5Rajendra S. Apte, MD, PhD6John F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MissouriJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MissouriJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MissouriJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MissouriDepartment of Neurology, Washington University School of Medicine, St. Louis, MissouriDepartment of Neurology, Washington University School of Medicine, St. Louis, MissouriJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri; Department of Medicine, Washington University, St. Louis, Missouri; Correspondence: Rajendra S. Apte, MD, PhD, Washington University School of Medicine, 660 South Euclid Avenue, Box 8096-06-0705, St. Louis, MO 63110.Purpose: Sphingosine-1-phosphate (S1P) plays a pivotal role in cells as a bioactive lipid mediator, with emerging evidence suggesting that it may play a role in retinal ganglion cell survival, axonal growth, retinal pigment epithelium (RPE) barrier function, and photoreceptor function. While previous studies have documented associated ophthalmic effects such as fingolimod-associated macular edema, the specific impact of S1P receptor modulators on inner and outer retinal layer thicknesses requires further elucidation. Design: Retrospective case series. Subjects: A total of 44 patients (86 eyes) with multiple sclerosis (MS) treated with fingolimod between 2011 and 2023 at the John L. Trotter Multiple Sclerosis Center at Washington University in St. Louis. Methods: Eligible participants were those with baseline and follow-up OCT images conducted at or prior to S1P initiation and at the most recent visit. The peripapillary retinal nerve fiber layer (pRNFL), ganglion cell layer (GCL), central subfield thickness (CST), macular volume (MV), RPE, and photoreceptor thickness were determined through OCT segmentation. Generalized estimating equations were constructed incorporating relevant covariates. Main Outcome Measures: Annualized rate of change of specified retinal layer thickness. Results: The mean age was 49.4 ± 10.8 years and time between baseline and follow-up OCTs ranged from 2 months to 6.4 years with a median of 1 year, interquartile range 0.42 to 2.33. The annualized rate of change of pRNFL and CST were 0.022 [–0.363, 0.406] μm/year, and −1.37 [−3.11, 0.38] μm/year, whereas GCL and MV showed significant thinning of −0.231 [−0.430, −0.032] μm/year and −0.024 [–0.047, −0.001] mm3/year, respectively. Retinal pigment epithelium and photoreceptor layer thickness remained largely stable over time at 0.070 [−0.140, 0.280] μm/year and 0.673 [−0.218, 1.561] μm/year, respectively. Conclusions: Patients with MS on S1P modulators exhibited significant GCL and MV thinning with outer retina layer thickness preservation, providing insight into the potential retinal effects of S1P modulation in the setting of MS-related neurodegeneration. Prospective studies with standardized imaging intervals and appropriate controls are needed to distinguish the specific retinal effect of S1P modulation from MS neurodegeneration and enable more precise OCT interpretation of the retina in monitoring MS disease progression. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.http://www.sciencedirect.com/science/article/pii/S2666914525001915Multiple sclerosisOCTPhotoreceptorsRNFLRPE |
| spellingShingle | Wilson X. Wang, MD, MPhil Helen Rossmiller, BS Henok Getahun, BS Aditya Santoki, BS Dana C. Perantie, MPH Robert T. Naismith, MD Rajendra S. Apte, MD, PhD Retrospective OCT Analysis of Sphingosine-1-Phosphate Modulator Fingolimod in Multiple Sclerosis Ophthalmology Science Multiple sclerosis OCT Photoreceptors RNFL RPE |
| title | Retrospective OCT Analysis of Sphingosine-1-Phosphate Modulator Fingolimod in Multiple Sclerosis |
| title_full | Retrospective OCT Analysis of Sphingosine-1-Phosphate Modulator Fingolimod in Multiple Sclerosis |
| title_fullStr | Retrospective OCT Analysis of Sphingosine-1-Phosphate Modulator Fingolimod in Multiple Sclerosis |
| title_full_unstemmed | Retrospective OCT Analysis of Sphingosine-1-Phosphate Modulator Fingolimod in Multiple Sclerosis |
| title_short | Retrospective OCT Analysis of Sphingosine-1-Phosphate Modulator Fingolimod in Multiple Sclerosis |
| title_sort | retrospective oct analysis of sphingosine 1 phosphate modulator fingolimod in multiple sclerosis |
| topic | Multiple sclerosis OCT Photoreceptors RNFL RPE |
| url | http://www.sciencedirect.com/science/article/pii/S2666914525001915 |
| work_keys_str_mv | AT wilsonxwangmdmphil retrospectiveoctanalysisofsphingosine1phosphatemodulatorfingolimodinmultiplesclerosis AT helenrossmillerbs retrospectiveoctanalysisofsphingosine1phosphatemodulatorfingolimodinmultiplesclerosis AT henokgetahunbs retrospectiveoctanalysisofsphingosine1phosphatemodulatorfingolimodinmultiplesclerosis AT adityasantokibs retrospectiveoctanalysisofsphingosine1phosphatemodulatorfingolimodinmultiplesclerosis AT danacperantiemph retrospectiveoctanalysisofsphingosine1phosphatemodulatorfingolimodinmultiplesclerosis AT roberttnaismithmd retrospectiveoctanalysisofsphingosine1phosphatemodulatorfingolimodinmultiplesclerosis AT rajendrasaptemdphd retrospectiveoctanalysisofsphingosine1phosphatemodulatorfingolimodinmultiplesclerosis |